Cosmos Health Inc. (COSM)
NASDAQ: COSM · Real-Time Price · USD
0.6280
-0.0609 (-8.84%)
Nov 25, 2025, 4:00 PM EST - Market closed
Cosmos Health Revenue
Cosmos Health had revenue of $17.11M in the quarter ending September 30, 2025, with 37.86% growth. This brings the company's revenue in the last twelve months to $59.79M, up 6.69% year-over-year. In the year 2024, Cosmos Health had annual revenue of $54.43M with 1.97% growth.
Revenue (ttm)
$59.79M
Revenue Growth
+6.69%
P/S Ratio
0.29
Revenue / Employee
$401,294
Employees
149
Market Cap
21.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.43M | 1.05M | 1.97% |
| Dec 31, 2023 | 53.38M | 3.03M | 6.02% |
| Dec 31, 2022 | 50.35M | -5.89M | -10.48% |
| Dec 31, 2021 | 56.24M | 833.33K | 1.50% |
| Dec 31, 2020 | 55.41M | 15.73M | 39.65% |
| Dec 31, 2019 | 39.68M | 2.59M | 6.99% |
| Dec 31, 2018 | 37.08M | 7.07M | 23.56% |
| Dec 31, 2017 | 30.01M | 23.26M | 344.28% |
| Dec 31, 2016 | 6.76M | 6.22M | 1,165.53% |
| Dec 31, 2015 | 533.80K | -7.11M | -93.01% |
| Dec 31, 2014 | 7.64M | 6.74M | 746.55% |
| Dec 31, 2013 | 902.37K | - | - |
| Jul 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Jul 31, 2012 | - | - | - |
| Jul 31, 2011 | - | - | - |
| Jul 31, 2010 | - | - | - |
| Jul 31, 2009 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COSM News
- 8 days ago - Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M - GlobeNewsWire
- 25 days ago - Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy - GlobeNewsWire
- 5 weeks ago - Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million - GlobeNewsWire
- 6 weeks ago - Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million - GlobeNewsWire
- 6 weeks ago - Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility - GlobeNewsWire
- 7 weeks ago - Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units - GlobeNewsWire
- 2 months ago - Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation - GlobeNewsWire
- 2 months ago - Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually - GlobeNewsWire